Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: Superior outcomes compared with chemotherapy alone and an analysis of prognostic factors

European Journal of Haematology

Volumn 91, Issue 4, 2013, Pages 304-314

  Yan, Chen Hua ^a   Wang, Jing Zhi ^a   Liu, Dai Hong ^a   Xu, Lan Ping ^a   Chen, Huan ^a   Liu, Kai Yan ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute leukemia; Allogeneic hematopoietic stem cell transplantation; Chemotherapy; Donor lymphocyte infusion; Haploidentical; Relapse

Indexed keywords

ACLACINOMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HARRINGTONINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; T CELL DEPLETION; TREATMENT DURATION;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOTHERAPY; DONOR LYMPHOCYTE INFUSION; HAPLOIDENTICAL; RELAPSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84884813720     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12168     Document Type: Article

References (44)

1. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA, Sanders JE, Storb R, Thomas ED. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989;7:50-7.
2. Frassoni F, Barrett AJ, Grañena A, Ernst P, Garthon G, Kolb HJ, Prentice HG, Vernant JP, Zwaan FE, Gratwohl A. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988;70:317-20.
3. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-44.
4. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first haematological relapse after allogeneic stem cell transplantation in adult with acute myeloid leukaemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukaemia working party. J Clin Oncol 2007;25:4938-45.
5. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation. J Clin Oncol 2002;20:405-12.
6. Spyridonidis A, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012;26:1211-17.
7. Frassoni F, Bacigalupo A. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003;31:687-93.
8. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000;26:511-16.
9. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
10. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004;103:790-5.
11. Huff CA, Fuchs EJ, Smith BD, et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006;12:414-21.
12. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G, Bonfichi M, Pagnucco G, Salvaneschi L, Bernasconi C. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23:607-12.
13. Takami A, Okumura H, Yamazaki H, et al. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Int J Hematol 2005; 82: 449-55.
14. Choi SJ, Lee JH, Lee JH, Kim S, Seol M, Lee YS, Lee JS, Kim WK, Chi HS, Lee KH. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004; 18: 1789-97.
15. Platzbecker U, Thiede C, Freiberg-Richter J, Helwig A, Mohr B, Prange G, Füssel M, Köhler T, Ehninger G, Bornhäuser M. Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose reduced conditioning followed by donor blood stem cells and GM-CSF. Ann Hematol 2001;80:144-9.
16. Huang XJ, Guo NL, Ren HY, Zhang YC, Gao ZY, Xu LP, Lu DP. The comparison of GVL effects between the patients receiving donor peripheral blood stem cells and donor lymphocytes after allogeneic bone marrow transplantation. J Peking University (health science) 2003;35:103-7.
17. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447-54.
18. Kato S, Yabe H, Yasui M, Kawa K, Yoshida T, Watanabe A, Osugi Y, Horibe K, Kodera Y. Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haploidentical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood. Bone Marrow Transplant 2000; 26:1281-90.
19. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008;112:3574-81.
20. Federmann B, Bornhauser M, Meisner C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008;40:13-19.
21. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLAmismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8:377-86.
22. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-50.
23. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065-73.
24. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006;38:291-7.
25. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-7.
26. Kurokawa T, Ishiyama K, Ozaki J, Yamashita Y, Iwaki N, Saito C, Arahata M, Kaya H, Yoshida T. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Int J Hematol 2010;91:661-9.
27. Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Rhee Fv Fv, DeRienzo S, O'Neal W, Lamb L, Henslee-Downey PJ. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 2004; 33: 389-396.
28. Or R, Hadar E, Bitan M, et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 2006;12:1295-301.
29. Pati AR, Godder K, Lamb L, Gee A, Henslee-Downey PJ. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995;15:979-81.
30. Ferster A, Bujan W, Mouraux T, Devalck C, Heimann P, Sariban E. Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant 1994;14:331-2.
31. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLAmismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007;92:414-17.
32. Yan CH, Liu DH, Xu LP, Liu KY, Zhao T, Wang Y, Chen H, Chen YH, Han W, Huang XJ. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 2012; 26: 868-76.
33. Zhao XS, Jin S, Zhu HH, Xu LP, Liu DH, Chen H, Liu KY, Huang XJ. Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012;47:499-507.
34. Zhao XS, Liu YR, Zhu HH, Xu LP, Liu DH, Liu KY, Huang XJ. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2012;91:183-92.
35. Tomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone marrow transplantation. N Engl J Med 1975;292:895-902.
36. Perkins NJ, Schisterman EF. The youden index and the optimal cut-point corrected for measurement error. Biom J 2005;47:428-41.
37. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a southwest oncology group/eastern cooperative oncology group study. Blood 2000;96:4075-83.
38. Moorman AV, Harrison CJ, Buck GAN, et al. Karyotype is an independent prognostic factor in acute lymphoblastic leukaemia: analysis of cytogenetic data from patients treated on the MRC UKALL XII/ECOG 2993 trial. Blood 2007;109:3189-97.
39. Raiola AM, Van Lint MT, Valbonesi M, et al. Factor predicting response and graft-versus-host disease after donor lymphocyte infusion: a study on 593 infusions. Bone Marrow Transplant 2003;31:687-93.
40. van de Donk NW, Kröger N, Hegenbart U, et al. Prognostic factor for donor lymphocyte infusion following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006, 37: 1135-1141.
41. Huang XJ, Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 2009;44:309-16.
42. Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004;89:1517-24.
43. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007;17:193-7.
44. Morris ES, MacDonald KP, Rowe V, et al. NKT cell- dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 2005;115:3093-103.